Results 71 to 80 of about 241,339 (286)

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. [PDF]

, 2012
Limited data exist regarding treatment patterns and outcomes in elderly patients with HER2-positive metastatic breast cancer (MBC). registHER is an observational study of patients (N = 1,001) with HER2-positive MBC diagnosed within 6 months of enrollment
Brufsky, Adam M, Feng, Shibao, Kaufman, Peter A, Mayer, Musa, Quah, Cheng S, Rugo, Hope S, Tripathy, Debu, Wang, Lisa I, Yardley, Denise A, Yood, Marianne Ulcickas   +9 more
core   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

Nuclear medicine procedures and the evaluation of male sexual organs: a short review [PDF]

, 2008
Sexuality consists of three aspects that are interrelated and inseparable, biological, physiological and social. The biological aspect considers the individual's capability to give and to receive pleasure.
Adenilson de Souza da Fonseca, Bernardo-Filho M., Beutel M. E., Bouchelouche K., Chaffanjon P. C., Choe W., Dennerstein L., Fanti S., Ganjoo K. N., Gerber G., Halac M., Hatzimouratidis H., Jana S., Kevin Carter, Kim C. K., Kolodny R. C., Kotzerke J., Kotzerke J., Kumar V., Lange P. H., Mario Bernardo-Filho, Masters W. H., Orhan I., Perkins A., Perkins A., Ravizzini G., Roivainen A., Ryu J., Saha G., Sebastião David Santos-Filho, Shen Y. Y., Sotiris Missailidis, Stelzner F., Sumich A. L., Timmermans L., Tóth G., Valdés Olmos R. A., Warren G. P., Willan B. D., Zuckier L. S.   +39 more
core   +4 more sources

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Can clinical factors be determinants of bone metastases in non-small cell lung cancer ?

Annals of Thoracic Medicine, 2007
Objective: The aim of this study was to investigate the correlations among symptoms, laboratory findings of bone metastasis and whole body bone scanning (WBBS) and the frequency of occurrence of bone metastases materials and methods:Hundred and six ...
Ursavas Ahmet, Karadag Mehmet, Uzaslan Esra, Rodoplu Erkan, Demirdogen Ezgi, Burgazlioglu Basak, Gozu R   +6 more
doaj  

Medication-related osteonecrosis of the jaw: clinical and practical guidelines [PDF]

, 2016
Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction, consisting of progressive bone destruction in the maxillofacial region of patients.
Allen, Bamias, Bedogni, Berenson, Brauner, Carlson, Coleman, Damm, Delmas, Delmas, Delmas, Dimopoulos, Fedele, Fizazi, Grbic, Guarneri, Hellstein, Hortobagyi, Kos, Lo, Marx, Mauri, Nussbaum, Papapoulos, Pompa, Qi, Qi, Reid, Ripamonti, Romeo, Rugani, Ruggiero, Ruggiero, Ruggiero, Saad, Saad, Scagliotti, Scoletta, Seth, Tenore, Vahtsevanos, Vandone, Yamazaki   +42 more
core   +2 more sources

Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

Molecular Oncology, EarlyView.
This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel, Peyman Zarrineh, Nathnael T. Tuffa, Jigar H. Sheth, Sumitra Mohan, Mudassar Iqbal, Sankari Nagarajan   +6 more
wiley   +1 more source

Neuron-specific enolase, histopathological types, and age as risk factors for bone metastases in lung cancer

Tumor Biology, 2017
Lung cancer is a malignant tumor with high metastatic ability and bone is the most common site of distant metastasis of it. However, the independent risk factors for bone metastases of lung cancer remain largely to be elucidated.
Yang Zhou, Wen-Zhao Chen, Ai-Fen Peng, Wei-Lai Tong, Jia-Ming Liu, Zhi-Li Liu   +5 more
doaj   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source